ArticleFrontiers in immunology2021
Case Report:
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Metabolic Checkpoints in Cutaneous Squamous Cell Carcinoma: ACSL1 and PPARD Orchestrate Lipid-Ferroptosis Crosstalk via Keratinocyte Remodeling.Applied biochemistry and biotechnology · 2026Article
- Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma-A Systematic Review.Dermatopathology (Basel, Switzerland) · 2026Review
- The broad spectrum of cancer and immunotherapy: achievements and limitations.Frontiers in immunology · 2025Review
- From neglect to necessity: the role of innate immunity in cutaneous squamous cell carcinoma therapy.Frontiers in immunology · 2025Review
- Endometriosis and Sjögren's syndrome: Bidirectional associations in population-based 15-year retrospective cohorts.Acta obstetricia et gynecologica Scandinavica · 2024Article
- Contezolid-Containing Regimen Successfully Treated Multiple Drug Resistance Mycobacterium Abscessus Complex Infection of Skin: A Case Report and Literature Review.Infection and drug resistance · 2024Article
- Non-Surgical Therapeutic Strategies for Non-Melanoma Skin Cancers.Current treatment options in oncology · 2023Review
- Therapeutic Cancer Vaccines for Nonmelanoma Skin Cancer.Current treatment options in oncology · 2023Review
- Ocular surface complications following biological therapy for cancer.Frontiers in toxicology · 2023Review
- Cancer-Derived Extracellular Vesicles as Biomarkers for Cutaneous Squamous Cell Carcinoma: A Systematic Review.Cancers · 2022Review
- Nutritional support for successful weaning in patients undergoing prolonged mechanical ventilation.Scientific reports · 2022Article
- Human Papillomavirus Infection and the Risk of Erectile Dysfunction: A Nationwide Population-Based Matched Cohort Study.Journal of personalized medicine · 2022Article
- Risk of primary Sjogren's Syndrome following human papillomavirus infections: a nationwide population-based cohort study.Frontiers in immunology · 2022Article
- Exposure to environmental air pollutants as a risk factor for primary Sjögren's syndrome.Frontiers in immunology · 2022Article
- Case report:Frontiers in immunology · 2022Article
- Sentiment analysis of tweets on alopecia areata, hidradenitis suppurativa, and psoriasis: Revealing the patient experience.Frontiers in medicine · 2022Article
- Bidirectional Relationship Between Osteoarthritis and Periodontitis: A Population-Based Cohort Study Over a 15-year Follow-Up.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of radiotherapy and immunotherapy improves the survival rate of patients with malignancies developed through escape from T-cell-mediated immune surveillance. Immune checkpoint inhibitors, such as anti-programmed cell death protein-ligand 1 (anti-PD-L1) antibody, are used to rescue exhausted T cells. Simultaneously, dendritic cells (DCs) which are antigen-presenting cells that can initiate T-cell activation, are used to induce a tumor-specific immune response. However, the synergistic antitumor efficacy of the aforementioned combinational immunotherapy with intratumoral injection of low-dose DCs has not been reported, and the underlying therapeutic mechanism requires further investigation. Herein, we present the special case of a psoriatic patient with cutaneous squamous cell carcinoma (cSCC) in the right inguinal region, these two diseases characterized by opposing contradiction, further complicating treatments and side-effect management efforts. To treat the intractable SCC without exaggerating psoriasis, we developed the triple-regimen therapy (TRT) with the intratumoral injection of low-dose autologous DCs and anti-PD-L1 combined with radiotherapy. The injected DCs were obtained simply through leukapheresis without prior G-CSF administration for mobilization nor tumor-antigen loading for expansion. The patient received three radiation doses (24, 18, and 18 Gy) combined with three intratumoral injections of anti-PD-L1 antibody (40, 60, and 120 mg) plus autologous DCs (80% of the DC subpopulation being CD16
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.